Trial Profile
A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of SCH 527123 in Subjects With Allergen-Induced Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Navarixin (Primary)
- Indications Allergic asthma
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 19 May 2010 Results were reported at the 106th International Conference of the American Thoracic Society.
- 12 Mar 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 12 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.